Nephrology News
Early NLR Changes Predict mRCC Immunotherapy Outcomes
Rises and decreases in neutrophil-to-lymphocyte ratio at 6 weeks after treatment with anti-PD-1/PD-L1 immune checkpoint blockade is associated with progression-free and overall survival.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/